Efficacy and Safety of One-Stage Hybrid Coronary Revascularization
Efficacy and Safety of One-Stage Hybrid Coronary Revascularization
Coronary revascularization could be accomplished either by percutaneous coronary intervention
 (PCI) or coronary artery bypass graft (CABG). PCI with drug-eluting stent (DES) implantation
 is featured by minimal invasive, low complication and rapid rehabilitation. CABG is
 characterized by improved long-term, event-free survival attributable to the use of left
 internal mammary artery (LIMA) graft. Hybrid coronary revascularization (HCR) consists of
 LIMA bypass to left anterior coronary descending artery (LAD) by minimal invasive direct
 coronary artery bypass (MIDCAB) and PCI of other stenosed coronary arteries with DES
 implantation. One-step HCR entails LIMA-LAD anastomosis performed through MIDCAB, immediately
 followed by PCI for non-LAD lesions, sometimes for diagonal branch, in the hybrid operating
 room. Limited data are available in comparing one-step HCR to PCI alone for the treatment of
 multivessel coronary artery disease(MVD). The current EAST-HCR study will investigate the
 efficacy and safety of one-step HCR for patients with MVD, as comparing to PCI alone.
Inclusion Criteria:

 1. 18 Years and older

 2. signed the informed consent

 3. indicated for revascularization, with possible bypass segment in LAD and amendable
 lesions by PCI in other vessels

 4. anatomy requiring as following: (1) Multivessel CAD involving the LAD (proximal or
 mid) and/or LM (ostial, mid-shaft or distal) with at least 1 other epicardial coronary
 artery requiring treatment in LCX or RCA, including: (2) LAD disease, and a major
 diagonal lesion, either bifurcation or independent in location, with both requiring
 revascularization (determined by QFR or FFR) (3) LM distal bifurcation lesion (Medina
 1,1,1), intended for 2-stent approach if randomized to PCI

 5. Heart team discussion after angiogram, with conclusion of suitable candidate for
 either PCI or HCR

 6. Able to tolerate and no plans to interrupt dual anti-platelet therapy for 3~12 months

 7. Willing to comply with 2-year clinical follow-up

 Exclusion Criteria:

 1. Previous cardiac or thoracic surgery

 2. Previous PCI of the LM and/or LAD within 12 months

 3. Totally occluded left main vessel

 4. Cardiogenic shock or LVEF <30%

 5. Previous STEMI within 30-day prior to randomization

 6. Concomitant vascular or other cardiac disease with plan of surgical treatment

 7. Indication for chronic oral anticoagulation therapy

 8. Previous stroke history within 6-month prior to randomization

 9. Survival expectation less than 3 years due to non-cardiac illness

 10. Allergy or hypersensitivity to any of the study drugs or devices used in the trial

 11. Enrolled in additional clinical study

 12. Informed consent not available or noncompliance with follow-up

 13. Pregnant